Identification of HLA I and II Alleles Using Next-Generation Sequencing

CeGaT has updated and expanded its HLA typing portfolio. In addition to HLA class I genes, HLA class II genes are now also analyzed via exome sequencing in a single workflow. This makes CeGaT’s updated HLA typing portfolio not only more comprehensive but also more time- and cost-efficient. Our flexible HLA service options thus create the optimal basis for your clinical or scientific questions.

The human leukocyte antigen (HLA) system comprises six classical HLA genes (class I HLA-A, -B and -C and class II HLA-DRB1, -DQB1 and -DPB1). These genes are responsible for the specific immune response in humans. The analysis of the HLA classes allows:

  • the verification of the individual response to drug therapy, including pharmacogenetics,
  • the HLA assignment of donor-recipient pairs for transplantation or
  • providing important information for cancer immunotherapy.

Furthermore, the HLA region is known to be associated with more than 100 multifactorial, complex diseases mainly of inflammatory and autoimmune pathogenesis. Next-generation sequencing-based HLA analysis helps you find out more about the functions and complex interactions of the HLA system. Discover our HLA typing portfolio and reap the benefits of rapid and accurate HLA allele identification:

CeGaT’s HLA-Classic service includes the analysis of high molecular weight DNA with a defined output of 6 Gb. All HLA class I and II genes are analyzed via exome sequencing in a single workflow. The data obtained includes not only the exome but also the mitochondrial genome (Twist Bioscience). 

CeGaT’s HLA-Flex service is feasible even with flexible DNA quality or quantity. The sequencing result can be adapted to your requirements and defined accordingly.

Our sequencing service provides reliable and accurate insights into HLA types and includes all steps from DNA extraction to data analysis. We are looking forward to discussing all options with you and supporting you in planning your clinical study or research project.  Benefit from our many years of expertise in the diagnostic field, our strict quality standards, and our practical knowledge.

Please feel free to contact us at rps@cegat.com for more information.

New Tech Note Released: Discover the Different Options of RNA Sequencing Designed for your Needs

Transcriptome sequencing is a very sensitive method to analyze coding- and non-coding RNAs of an organism, tissue, or cell culture. To guide our customer in finding the best solution for his research project or clinical study, we released our brand-new Tech Note. This Tech Note visualizes our workflow, which has been specifically designed to meet our customer’s needs.

The transcriptome comprises all RNAs, which are transcribed in an organism or cell at a certain point in time. It may be influenced by the metabolic state or by external factors, such as drugs or diseases. Depending on the experimental setup or research objective, total RNA or messenger RNA (mRNA) can be sequenced. Besides common species such as humans, rats, or mice, we can also sequence the transcriptome of plants, fungi, bacteria, viruses, insects, fish, and many more. We accept either purified RNA, tissue, or cells. Our latest Tech Note guides you through the CeGaTs Transcriptome portfolio to help you find the best solution for your project.

Coding transcriptome sequencing (CTS) to capture influences on gene expression

Only about 1-5% of the transcriptome corresponds to messenger RNA. This requires high-quality RNA from cells, plants, and fresh or frozen tissues. Polyadenylation at the 3′ end of mRNA is found in most eukaryotes and is used to separate mRNA from total RNA. This mRNA enrichment results in increased sequencing depth. Even lowly expressed or rare transcripts can be detected. Coding transcriptome sequencing is commonly used to determine gene expression and for differential gene expression analysis or the characterization of alternative splicing patterns.

Whole transcriptome sequencing (WTS) for the identification and characterization of known or novel transcripts all over the transcriptome

The entity of coding RNA plus a variety of different non-coding RNAs is comprised of total RNA. Since ribosomal RNA comprises most of the total RNA, we recommend rRNA depletion before we start with the sequencing library preparation. To achieve the best possible results, CeGaT offers different kits depending on the different sample materials. Total RNA can be obtained from blood, cells, tissue as well as fresh frozen tissue. In addition, CeGaT offers special kits that can handle FFPE-embedded tissue. The analysis of total RNA enables a genome-wide comprehensive overview of the transcriptome of an organism or cell to investigate introns, exons, or splicing mechanisms.

CeGaT´s transcriptome sequencing service offers reliable and accurate insights into RNA from extraction to data analysis. With our long-standing expertise in the diagnostic field, our clients benefit from strict quality control standards and therefore high-quality results.

All sequencing data are stored in-house and are processed in-house by our own bioinformatics unit. We offer sophisticated solutions for your needs and different options for data transfer. Our detailed project report is delivered with every sequencing order by your personal contact person at CeGaT.

For further information, please do not hesitate to contact us at rps@cegat.com.

Transcriptome Sequencing – Tech Note

Liquid Biopsies – Utilize the Potential of cfDNA with CeGaT’s New NGS-based Product Portfolio

CeGaT expands its Liquid Biopsy product portfolio with two UMI (Unique Molecular Identifier) based NGS analyses. Our broad Liquid Biopsy product portfolio offers a suitable approach for every clinical or research question. CeGaT`s LB Focus panel detects variants known to be driver mutations in 36 genes relevant to a broad spectrum of tumor entities. LB Exploratory includes the analysis of 523 genes using Illumina’s TSO500 ctDNA assay. Both products allow for highly sensitive detection of variants present in the circulating tumor DNA (ctDNA), with a sensitivity of up to 0.25% and 0.5% NAF (novel allele frequency), respectively.

The minimally invasive analysis of a tumor’s genetic profile is called liquid biopsy. The blood sample collection required for this purpose can be performed in an uncomplicated and repeatable manner. Furthermore, circulating cell-free DNA (cfDNA) has a very short half-life and, consequently, always reflects the current state of the disease. Liquid biopsies thus present an ideal way of complementing or even replacing tissue-based molecular genetic tumor diagnostics.

There are various feasible applications for the clinical use of liquid biopsies:

  • Monitoring treatment response,
  • Disease monitoring,
  • Detection of minimal residual disease after surgery,
  • Patient stratification,
  • Early detection and profiling of resistance to therapy.

The broad Liquid Biopsy product portfolio allows CeGaT to support your project optimally, independent of your clinical or research question. Benefit from the capabilities of our Liquid Biopsy product portfolio:

  • LB Target: Specific tumor variants can be tracked during therapy using digital droplet PCR (ddPCR).
  • LB Focus: The LB Focus panel allows for highly sensitive monitoring and follow-up of cancer patients during and after therapy.
  • LB Exploratory: enables comprehensive genomic profiling of the tumor and, moreover, the evaluation of key immuno-oncology biomarkers like TMB (Tumor Mutational Burden).
  • LB Flex: Using LB Flex for cfDNA analysis, you have the possibility to use a whole-exome approach or a CeGaT panel of choice.

We would be happy to discuss all options and support you in planning your clinical trial or research project. Your project will benefit from our long-standing expertise in the diagnostic field and, thus, strict quality standards, as well as practical knowledge.

For further information, please do not hesitate to contact us at rps@cegat.com.

More About Our Liquid Biopsy Product Portfolio

Watch Our Free Webinar with Hamilton Robotics: “Automating NGS Workflows for Precision Medicine-Oncology.”

The concept of precision medicine has gained a lot of attention within the last years, especially regarding cancer patients’ treatment. NGS can help to further advance the field and make a real difference for researchers, physicians, and ultimately, for patients.

The focus of this webinar is CeGaT’s experience in automating NGS workflows for personalized medicine in the field of oncology. Learn more about our motivation and approach to automating our library preparation workflows and get to know the latest trends and developments in the field of precision medicine. Using examples from practice, we will present the importance and opportunities of NGS in this context. Find out more in our webinar with Hamilton Robotics on May 6, 2021.

Speakers & content:

Dr. Elisabeth Maritschnegg, Product Manager Oncology at CeGaT GmbH

Dr. Gabriela Boza-Moran, Scientific Content Manager at Hamilton Robotics

Dr. Elisabeth Maritschnegg will describe the drivers behind the need for automating CeGaT’s NGS workflows and the benefits of their current automated systems. Moreover, she will illustrate the benefits of CeGaT’s genomic services through two case studies.

At the conclusion of the webinar, Dr. Gabriela Boza-Moran will present some of the commercial solutions that Hamilton Robotics can provide to customers using NGS in Precision Medicine-Oncology studies.

Watch our free webinar

If you have any questions, please do not hesitate to contact us at rps@cegat.com.

We would be happy to discuss all options for your clinical trial or research project. More information about the Research and Pharma Solutions portfolio can be found here.

Join Our Webinar with Hamilton Robotics: “Automating NGS Workflows for Precision Medicine-Oncology.”

The concept of precision medicine has gained a lot of attention within the last years, especially regarding cancer patients’ treatment. NGS can help to further advance the field and make a real difference for researchers, physicians, and ultimately, for patients.

We invite you to participate in CeGaT’s joint webinar with Hamilton Robotics. The webinar will focus on CeGaT’s experience in automating NGS workflows for Precision Medicine-Oncology. We will grant an insight into our motivation and approach for automating our library preparation workflows. Furthermore, we will talk about developments in the field of precision medicine. Giving practical examples, we will outline the role and possibilities of NGS in this concept. Join our free webinar on May 6, 16:00 CET.

Speakers & content:

Dr. Elisabeth Maritschnegg, Product Manager Oncology at CeGaT GmbH

Dr. Elisabeth Maritschnegg will describe the drivers behind the need for automating CeGaT’s NGS workflows and the benefits of their current automated systems. Moreover, she will illustrate the benefits of CeGaT’s genomic services through two case studies.

Dr. Gabriela Boza-Moran, Scientific Content Manager at Hamilton Robotics

At the conclusion of the webinar, Dr. Gabriela Boza-Moran will present some of the commercial solutions that Hamilton Robotics can provide to customers using NGS in Precision Medicine-Oncology studies.

If you have any questions in advance, please do not hesitate to contact us at rps@cegat.com.

We would be happy to discuss all options for your clinical trial or research project. You can find more information on the Research and Pharma Solutions portfolio here.